Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation (VCEL) pioneers patient-specific cellular therapies for sports medicine and severe burn care through advanced regenerative science. This dedicated news hub provides investors and medical professionals with timely updates on the company’s progress in transforming treatment paradigms.
Access authoritative information on FDA approvals, clinical trial outcomes, and strategic initiatives shaping the future of cell-based therapies. Our curated collection includes:
- Quarterly earnings reports and financial disclosures
- Product launch announcements and manufacturing updates
- Research collaborations and intellectual property developments
- Regulatory milestones for novel treatment platforms
Bookmark this page for streamlined tracking of Vericel’s advancements in autologous cell therapies, including innovations in cartilage repair and burn wound management. Stay informed about developments that impact both patient care and investment considerations in the evolving biologics sector.
Vericel Corporation (NASDAQ:VCEL) announced that its partner, MediWound Ltd., received a complete response letter (CRL) from the FDA regarding the Biologics License Application for NexoBrid, a treatment for severe burns. The FDA cited issues in the Chemistry, Manufacturing, and Controls (CMC) section, requiring additional information and inspections, which were hindered by COVID-19 travel restrictions. The FDA also highlighted concerns from good clinical practice inspections affecting the study's efficacy. Vericel remains committed to addressing these issues to expedite NexoBrid's approval.
Vericel Corporation (NASDAQ:VCEL) announced that CEO Nick Colangelo will present a company overview at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 4:40 p.m. Eastern Time. The event will be conducted virtually, allowing investors to access a live webcast via the Investor Relations section of Vericel's website. Vericel specializes in advanced therapies for sports medicine and severe burn care, offering MACI and Epicel as leading cell therapy products.
Vericel Corporation (NASDAQ:VCEL) announced the immediate appointment of Lisa Wright to its Board of Directors. With Ms. Wright's addition, the Board now comprises eight directors, seven of whom are independent. Wright, President and CEO of Community Health Choice, has extensive experience in the healthcare sector, having held leadership positions at WellCare and UnitedHealth Group. Her expertise in payer and provider environments is expected to enhance Vericel's strategic initiatives and growth trajectory. This appointment underscores the company's commitment to diverse skills on its Board.
Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present an overview of the company at the Canaccord Genuity Virtual Musculoskeletal Conference. The presentation is scheduled for May 20, 2021, at 9:30 a.m. Eastern Time. Interested parties can access a live webcast through the Investor Relations section of the Vericel website.
Vericel specializes in advanced therapies for sports medicine and severe burn care, offering innovative products such as MACI® and Epicel®.
Vericel Corporation (NASDAQ:VCEL) reported a 30% increase in total net revenue for Q1 2021, reaching $34.6 million, up from $26.7 million in Q1 2020. Notable revenue contributions include $23.8 million from MACI® and $9.8 million from Epicel®. The gross margin improved to 66%, and adjusted EBITDA rose to $4.6 million. Full-year revenue guidance is raised to $165-$168 million.
Vericel ended Q1 with $110 million in cash and no debt, indicating a strong financial position.
Vericel Corporation (NASDAQ:VCEL) has scheduled a conference call on May 5, 2021, at 8:30 am (EDT) to discuss its first-quarter 2021 financial results. The earnings call can be accessed live on the company's website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing MACI® and Epicel® cell therapy products in the U.S. The company also holds commercial rights to NexoBrid®, aimed at severe thermal burns. For further details, investors can visit the Investor Relations section of the Vericel website.
Vericel Corporation (NASDAQ:VCEL) will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 4:30 p.m. ET. The presentation will be led by President and CEO Nick Colangelo. A live webcast of the event will be available on Vericel's Investor Relations website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing MACI® and Epicel®, with exclusive rights for NexoBrid® in North America.
Vericel Corporation (NASDAQ:VCEL) announced that President and CEO Nick Colangelo will present a company overview at the Oppenheimer 31st Annual Healthcare Conference. The virtual presentation is scheduled for March 17, 2021, at 10:00 a.m. Eastern Time. A live webcast will be available on the Investor Relations section of the Vericel website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing cell therapy products MACI® and Epicel® in the U.S., and holds exclusive rights to NexoBrid® for severe thermal burn treatment.
Vericel Corporation (NASDAQ:VCEL) announced that CFO Joe Mara will present at the H.C. Wainwright Virtual Global Life Sciences Conference. The presentation will provide a company overview and will be accessible via webcast on March 9, 2021, at 7:00 a.m. ET. Vericel specializes in advanced therapies for sports medicine and severe burns, marketing two major products: MACI® for cartilage repair and Epicel® for skin replacement in burn patients. The company also holds rights to NexoBrid®, aimed at severe thermal burn debridement.
Vericel Corporation (NASDAQ:VCEL) reported strong financial results for Q4 2020, with total net revenue increasing 15% to $45.2 million. Key highlights include MACI® revenue of $34.7 million and Epicel® revenue of $9.6 million, contributing to a gross margin of 74%. The company achieved a net income of $12.2 million ($0.25 per share), up from $9.5 million in Q4 2019. For full-year 2021, total net revenue is expected to grow 30%-32%, aiming for approximately $161 to $164 million. Analysts will discuss these results in today's conference call at 8:30 AM ET.
FAQ
What is the current stock price of Vericel (VCEL)?
What is the market cap of Vericel (VCEL)?
